Why Lucid Diagnostics Inc.’s (LUCD) Stock Is Up 27.43%
As of Friday, October 23, Lucid Diagnostics Inc.’s LUCD share price has surged by 27.43%, which has investors questioning if this is right time to sell.Michael Rose
Stock Evaluator: Lucid Diagnostics Inc. (LUCD)
Lucid Diagnostics Inc. LUCD
$0.41
0.08
25.42%
October 23, 2026 4:00:00 PM
EST
Volume: 110,900,828
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company’s flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Commentary & Analysis
Why Lucid Diagnostics Inc.’s (LUCD) Stock Is Up 29.45%
As of Friday, October 23, Lucid Diagnostics Inc.’s LUCD share price has surged by 29.45%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Lucid Diagnostics Inc.’s (LUCD) Stock Is Down 5.85%
As of Thursday, October 22, Lucid Diagnostics Inc.’s LUCD share price has dipped by 5.85%, which has investors questioning if this is right time to buy.Michael Rose
Why Lucid Diagnostics Inc.’s (LUCD) Stock Is Up 8.55%
As of Wednesday, October 21, Lucid Diagnostics Inc.’s LUCD share price has surged by 8.55%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Lucid Diagnostics Inc.’s (LUCD) Stock Is Down 14.65%
As of Tuesday, October 20, Lucid Diagnostics Inc.’s LUCD share price has dipped by 14.65%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | LUCD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $78.5 | $404.5 | 20% |
|
| Shares Out (Mil) | 183.1 | 41.2 | 74% |
|
| Institutional Ownership | 84.6% | 83.3% | 53% |
|
| Float (Mil) | 140.8 | 35.5 | 67% |
|
| Beta | 1.08 | 0.85 | 64% |
|
| Avg Daily Volume (000s) | 18,117 | 259 | 98% |
|
| Price Change (52-week) |
(66.3%) | 62.9% | 13% |
|
| Growth | LUCD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | (47.5%) | (4.8%) | 8% |
|
| EPS (5yr) | (3.3%) | 10.6% | 27 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 4 | |
| Current EPS | ($0.057) | ($0.243) | ($0.165) | |
| Month Ago EPS | ($0.057) | ($0.243) | ($0.165) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.053) | ($0.237) | ($0.170) | |
| Year/Year Chg | (28.8%) | (64.9%) | (80.5%) | |
| Financials | LUCD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5 | $155 | 6% |
|
| Net Income (TTM) (Mil) | ($52) | ($9) | 16% |
|
| EPS (TTM) | ($0.462) | ($0.400) | 28% |
|
| Operating Cash Flow (TTM) (Mil) | ($47) | ($2) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $1 | 49% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $28 | 15% |
|
| Enterprise Value (Q1) (Mil) | $175 | $437 | 25% |
|
| Valuation | LUCD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.85 | 2.52 | 86% |
|
| P/E | na | 26.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.5 | na |
|
| Ratios | LUCD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (21.7%) | 59.0% | 3% |
|
| Net Margin | (959.8%) | (6.9%) | 0% |
|
| ROA | (134.7%) | (12.2%) | 4% |
|
| ROE | 293.3% | (10.5%) | 99% |
|
| Liabilities to Assets | 71.9% | 47.2% | 67% |
|
| F-Score | 6 | 4 | 67% |
|
Lucid Diagnostics Inc. did not pass any screens on 10/23/2026.
